Search

Your search keyword '"Song, Linjiang"' showing total 206 results
Start Over Author "Song, Linjiang"
206 results on '"Song, Linjiang"'

10. Estradiol pretreatment in GnRH antagonist protocol for IVF/ICSI treatment

Author

Zhu Shaomi, Lv Zhexi, Song Linjiang, Zhang Qinxiu, Fan Yiyue, and Li Junjun

Subjects
estradiol, gnrh antagonist, ivf/icsi, meta-analysis, Medicine
Abstract

We conducted a systematic review and meta-analysis of all published data to determine the impact of estradiol pretreatment on reproductive outcomes and ovary stimulation characteristics for in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment with gonadotropin-releasing hormone (GnRH) antagonist protocol. MEDLINE, EMBASE, Cochrane Library, Web of Science, and China National Knowledge Infrastructure were searched, and any randomized controlled trials associated with estradiol pretreatment in GnRH antagonist protocol were included. Seven studies (1,236 patients) were included in the present study. The pooled data from the meta-analysis demonstrated no significant difference in ongoing pregnancy rate (odds ratio (OR): 0.92 (95% CI: 0.69–1.21; P = 0.53) and live birth rate OR: 0.98 (95% CI: 0.74–1.30; P = 0.90) between patients with and those without estradiol pretreatment in GnRH antagonist protocol. Duration of gonadotropin exposure, gonadotropin consumption, and the number of cumulus–oocyte complexes were not significantly different between groups. Luteal estradiol pretreatment in IVF/ICSI cycles with GnRH antagonist protocol in normal ovary responding population does not affect the reproductive outcomes. It is an encouraging option to facilitate cycle scheduling in GnRH antagonist protocol, for luteal estradiol pretreatment does not increase the duration of gonadotropin exposure or gonadotropin consumption.

Published
2022
Full Text
View/download PDF

21. Programmable double-unlock nanocomplex self-supplies phenylalanine ammonia-lyase for precise phenylalanine deprivation of tumors

Author

Ou, Chunqing, primary, Xiao, Meijia, additional, Zheng, Xinyue, additional, Huang, Xianzhou, additional, Yang, Suleixin, additional, Leng, Yingying, additional, Liu, Xiaowei, additional, Liang, Xiuqi, additional, Song, Linjiang, additional, You, Yanjie, additional, Yao, Shaohua, additional, and Gong, Changyang, additional

Published
2023
Full Text
View/download PDF

36. Regulatory Mechanisms of LncRNAs in Cancer Glycolysis: Facts and Perspectives

Author

Huang,Peng, Zhu,Shaomi, Liang,Xin, Zhang,Qinxiu, Luo,Xiaohong, Liu,Chi, and Song,Linjiang

Subjects
Cancer Management and Research
Abstract

Peng Huang, Shaomi Zhu, Xin Liang, Qinxiu Zhang, Xiaohong Luo, Chi Liu, Linjiang Song Reproductive & Women-Children Hospital, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People’s Republic of ChinaCorrespondence: Linjiang Song; Chi LiuReproductive & Women-Children Hospital, School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, People’s Republic of ChinaEmail linjsong_scu@163.com; liuchi1985@163.comAbstract: Cancer cells exhibit distinct metabolic characteristics that employ glycolysis to provide energy and intermediary metabolites. This aberrant metabolic phenotype favors cancer progression. LncRNAs are transcripts longer than 200 nucleotides that do not encode proteins. LncRNAs contribute to cancer progression and therapeutic resistance and affect aerobic glycolysis via multiple mechanisms, including modulating glycolytic transporters and enzymes. Further, dysregulated signaling pathways are vital for glycolysis. In this review, we highlight regulatory mechanisms for lncRNAs in aerobic glycolysis that provide novel insights into cancer development. Moreover, a comprehensive understanding of the regulatory mechanisms of lncRNAs in aerobic glycolysis can provide new strategies for clinical cancer management.Keywords: lncRNA, cancer progression, glycolysis, signaling pathway

Published
2021

47. Baicalin triggers apoptosis, inhibits migration, and enhances anti‐tumor immunity in colorectal cancer via TLR4/NF‐κB signaling pathway.

Author

Song, Linjiang, Zhu, Shaomi, Liu, Chi, Zhang, Qinxiu, and Liang, Xin

Subjects
*COLORECTAL cancer, *CELLULAR signal transduction, *NF-kappa B, *MYELOID-derived suppressor cells, *IMMUNITY
Abstract

Aberrant activation of the nuclear factor‐kappa B (NF‐κB) signaling pathway is closely implicated in colorectal cancer (CRC) growth, metastasis, and immune escape. In the present study, we reported natural derived compound of baicalin (BA), an efficient inhibitor of NF‐κB, with good anti‐tumor effect on CRC. CCK8 and colony formation assays showed that Baicalin significantly inhibit viability and proliferation in HCT‐116 and CT26 cells. Additionally, Baicalin dramatically triggers mitochondria‐mediated apoptosis in both HCT‐116 and CT‐26 cells, which is evidenced by loss of mitochondrial membrane potential and elevated cellular reactive oxygen species level. Treatment with Baicalin suppresses migration and invasion of CT26 cells by impairing TLR4/NF‐κB signaling pathway. What's more, administration of Baicalin significantly retarded tumor growth rate in a subcutaneous xenograft tumor mouse model of CT26 cells. Treatment with Baicalin could ameliorate tumor immunosuppressive environment by downregulation of PD‐L1 expression and proportion of myeloid‐derived suppressor cells (MDSCs) and upregulation of percent of CD4+ and CD8+ T cells in CT26 tumors, thus improving anti‐tumor immunity. In conclusion, our study demonstrated that baicalin triggers apoptosis, inhibits migration, and enhances anti‐tumor immunity in colorectal cancer via TLR4/NF‐κB signaling pathway, suggesting it might serve as a potential candidate drug for the treatment of CRC. Practical applications: In the present study, we reported natural derived compound of baicalin (BA), an efficient inhibitor of NF‐κB, with good anti‐tumor effect on CRC. We demonstrated that baicalin triggers mitochondria‐mediated apoptosis, inhibits migration, and improves anti‐tumor immunity in colorectal cancer via TLR4/NF‐κB signaling pathway. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results